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Introduction
To date, seven human coronaviruses (HCoVs) have been identi-
fied, of which four (NL63, HKU1, OC43 and 229E) are known 
to be endemic among humans1–4. Endemic HCoV types are 
detected in a small but non-negligible proportion of respira-
tory tract infections; mild cases occur across a wide age-range 
and severe disease is predominant in young children and the 
elderly5–8. A further three HCoVs have emerged in recent years 
and caused epidemics: SARS-CoV the agent of severe acute 
respiratory syndrome in China9, MERS-CoV the cause of Mid-
dle East respiratory syndrome in the Middle-East10 and most 
recently SARS-CoV-2, the aetiological agent of the current pan-
demic of coronavirus disease 2019 (COVID-19)11. To date, there 
are limited preventive options against HCoV infections and no 
effective anti-viral treatment12. Understanding the epidemiol-
ogy of HCoVs can play a critical role in prediction, prevention 
and control of HCoV infection. In addition, data on endemic 
HCoVs may inform expectations for SARS-CoV-2 if it becomes 
endemic. Our study aims to describe the circulation patterns 
of HCoVs (OC43, 229E, and NL63) over time using data from 
a long-term surveillance programme in a rural coastal setting 
in Kenya, 3° south of the equator.
Methods
Study setting
A prospective study was established in 2007 for the long-term 
continuous respiratory virus surveillance among pneumonia 
admissions to Kilifi County Hospital (KCH)6 in order to develop 
improved epidemiological understanding, estimate disease bur-
den and provide suitable baseline data for future vaccine stud-
ies. KCH is the referral hospital within the Kilifi Health and 
Demographic Surveillance System (KHDSS), in the north-
ern coastal region of Kenya13. The location experiences two 
rainy seasons approximately from April to July and October to 
December, with median maximum temperature of 33°C (IQR: 
31–36), median minimum temperature of 23°C (IQR: 22–24), 
and median relative humidity of 78% (IQR: 71–87) (unpublished 
weather station data). Children aged 1 day to 59 months admit-
ted to KCH with clinical symptoms of severe or very severe 
pneumonia were recruited. Written informed consent was sought 
from parents/guardians of the children prior to sample collec-
tion. In this paper we define severe pneumonia as history of 
cough or difficulty breathing and chest indrawing while very 
severe pneumonia is defined as history of cough or difficult 
breathing and at least one of inability to feed, prostration, uncon-
sciousness, or oxygen saturation of <90% by fingertip pulse oxi-
metry. We use the term pneumonia to refer to all cases of clini-
cally severe or very severe pneumonia14. The variables extracted 
from the hospital surveillance database include; Demographic 
characteristics (sex, KHDSS residency status, age), presence/
absence of clinical features (history of cough, difficulty breath-
ing, cyanosis, nasal flaring, chest indrawing, crackles, wheeze, 
inability to drink, vomits everything, fever defined as axillary 
temperature ≥37.5°C , oxygen saturation levels, conscious 
level: agitated, lethargic, prostration or unconscious, pneu-
monia status: severe or very severe), laboratory test results 
for RSV (A and B), rhinovirus, HCoVs (NL63, OC43, 229E), 
influenza (A, B and C), parainfluenza virus (1–4), adenovirus, 
and human metapneumovirus, and hospitalisation outcomes 
(admission to the high dependency unit, discharge outcomes; 
alive or dead)
Laboratory methods
Specimens collected between January 2007 and December 
2019 were processed and screened for three HCoVs (OC43, 
NL63 and 229E) and at least 12 other respiratory viral patho-
gens using real-time polymerase chain reaction (RT-PCR). 
Sample testing was initially performed in 2007 using the 
LightCycler Fast Start DNA MasterPLUS HybProbe kit 
(Roche)6, then multiplex RT-PCR using Qiagen Quantifast mul-
tiplex RT-PCR kit (Qiagen, United Kingdom) in triplex sets 
on an ABI 7500 system, from January 2007 until the present 
day15,16; additionally, a proportion of samples were tested using 
a 33-pathogen multiplex quantitative PCR (FTD Resp-33, Fast 
Track Diagnostics, Sliema, Malta) as part of the multi-country 
PERCH study17, between August 2011 and December 2013. A 
variety of collection methods was used: nasopharyngeal flocked 
swab, nasal wash or combined nasopharyngeal swab and 
oropharyngeal swab.
Data analysis
Data analysis was done using STATA version 13.0 (Stata Corp, 
College Station Texas, USA). Summary statistics (counts, pro-
portions, measures of central tendency and variation) are 
presented for continuous and categorical data as appropriate. 
We estimated unadjusted odds ratios to measure the association 
between demographic and clinical characteristics of the study 
participants and testing positive for HCoV. Three Poisson regres-
sion models, one for each HCoV type, were used to investigate 
the presence of seasonality. In the models a trend variable was 
included and residuals plotted against month. Identification of 
a strong pattern by visual inspection of the residual plots would 
suggest presence of seasonality. The chi-square test of pro-
portional trends was used to test for a linear trend in the pro-
portions of samples tested or not tested for HCoV over time. 
To check for an association between categorical variables 
the chi-square test of association or Fisher’s exact test was 
used as appropriate. The analysis code is provided as Extended 
data18.
Ethical approval
This study was approved by the Kenya Medical Research 
Institute Scientific Ethics Review Unit (Approval number: 
KEMRI/SERU/CGMR-C/027/3178).
Results
Characteristics of patients infected with HCoVs
During the 13 years of surveillance, there were 49,409 pae-
diatric admissions of children aged 0–59 months at KCH. A 
total of 11,445 (23.2%) admissions were due to severe (n= 
7808, 68%) and very severe (n=3637, 32%) pneumonia. Out of 
the eligible cases, 69.5% (n=7957) were tested for the three 
HCoVs while the remainder were not tested due to refusal of 
consent (13.8%), discharge (13%) or death (3.7%) prior to 
sample collection. Cases untested did not differ from those 
tested in age distribution or sex ratio, but were more likely to 
be very severe (40.0% versus 28.3%, Fishers exact P-value 
<0.001).
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Of the 7957 samples tested, 5312 (66.7%) were aged <1 year, 
1454 (18.3%) were aged 12–23 months, 620 (7.8%) were aged 
24–35 months and 571 (7.2%) were in the 36–59 months age 
band. The proportion of tested individuals with elevated axil-
lary temperature (≥37.5°C), cough and difficulty breathing was 
58.3%, 83.2%, 92.6%, respectively. A total of 314 (3.9%) tested 
positive for at least one of the three HCoV targets. Among 
the HCoV positives, 129 (41.1%) had OC43, 99 (31.5%) 
had 229E, 74 (23.6%) had NL63 and 12 (3.8%) had coinfec-
tions between the three HCoV types. Among all the samples 
tested, the overall prevalence of NL63 was 1% (n=80), 1.7% for 
OC43 (n=137) and 1.4% for 229E (n=109).
The characteristics of the patients positive for any and for 
each HCoV type or infection combination are described in 
Table 1. HCoV positive cases were predominantly children 
aged <1 year (66.2%) and those aged 12–23 months (18.2%). 
The burden of infection with at least one HCoV, among all 
pneumonia admissions, was highest in infants and decreased 
with increasing age (2.6% for those under 1 year and 0.7% for 
12–23 months). The same pattern was seen for each individual 
HCoV type (not shown). However, the proportion of samples 
testing positive (3.9%) for HCoV did not vary with age group 
(Fisher’s exact p-value = 0.753). Among all HCoV positive par-
ticipants, mean age was 11 months (median 7 months), there 
Table 1. Demographic and clinical characteristics of study children (aged under 5 years) admitted with severe or 












n (%) n (%) n (%) n (%) n (%)
Age (months) Mean (SD) 11.9 (11.2) 11.0 (11.9) 12.1 (12.8) 6.9 (7.4) 11.4 (11.9)
Median (IQR) 8 (3-20) 7 (2-15) 8 (2-19) 5.5 (2-8.5) 7 (2-16)
Age categories 0–11 months 49 (66.2) 87 (67.4) 61 (61.6) 12 (91.7) 208 (66.2)
12–23 months 11 (14.9) 24 (18.6) 22 (22.2) 0 (0.00) 57 (18.2)
24–35 months 11 (14.9) 8 (6.2) 9 (9.1) 1 (8.3) 29 (9.2)
36–59 months 3 (4.0) 10 (7.8) 7 (7.1) 0 (0.00) 20 (6.4)
Sex Female 22 (29.7) 60 (46.5) 36 (36.4) 6 (50.0) 124 (39.5)
Male 52 (70.2) 69 (53.5) 63 (63.6) 6 (50.0) 190 (60.5)
Pneumonia status Severe 49 (66.2) 101 (78.3) 76 (76.8) 10 (83.3) 236 (75.2)
Very severe 25 (33.8) 28 (21.7) 23 (23.2) 2 (16.7) 78 (24.8)
Clinical 
presentation
Cough 55 (74.3) 112 (86.8) 85 (85.9) 12 (100.00) 264 (84.1)
Breathing difficulty 67 (90.5) 118 (91.5) 94 (95.0) 10 (83.3) 289 (92.1)
Fever* 43 (58.1) 75 (58.1) 54 (54.6) 10 (83.3) 182 (58.0)
Prostrate/unconscious 17 (23.0) 18 (14.0) 14 (14.1) 1 (8.3) 50 (15.9)
Chest Indrawing 65 (87.8) 122 (94.6) 89 (89.9) 12 (100.00) 288 (91.7)
Wheeze 7 (9.5) 16 (12.5) 18 (18.2) 0 (0.0) 41 (13.1)
Crackle 27 (36.5) 44 (34.1) 40 (40.4) 3 (25.0) 114 (36.3)
Nasal flaring 40 (54.1) 66 (51.2) 54 (54.6) 6 (50.0) 166 (52.9)
Shock* 12 (16.2) 10 (7.8) 6 (6.1) 0 (0.00) 28 (8.9)
Hypoxemia (O2 <90%) 12 (16.2) 14 (10.9) 13 (13.1) 1 (8.3) 40 (12.7)
Cyanosis 1 (1.4) 1 (0.8) 1 (1.0) 0 (0.00) 3 (1.0)
Inability to drink/feed 5 (6.8) 11 (8.5) 7 (7.1) 0 (0.00) 23 (7.3)
Vomits everything 7 (9.5) 6 (4.7) 0 (0.00) 0 (0.00) 13 (4.14)
Duration of hospital 
stay
Mean (SD) 6.3 (6.8) 5.7 (6.1) 5.2 (5.5) 3.8 (2.3) 5.6 (6.0)
Median (IQR) 4 (3-6) 3 (2-7) 3 (2-6) 6.5 (3-10) 4 (2-6)
Outcomes HDU* 27 (36.5) 31 (24.0) 22 (22.2) 2 (16.7) 82 (26.1)
Died 10 (13.5) 10 (7.8) 7 (7.1) 0 (0.00) 27 (8.6)
* Fever is defined as axillary temperature ≥37.5°C, shock is defined as capillary refill of >3 seconds, temperature gradient or weak pulse 
volume. HDU indicates study participants who were critically ill and were transferred from tde general ward to tde high dependency unit.
** tde high proportions of cough, breatding difficulty, chest indrawing, hypoxemia, prostrate/unconscious and inability to drink/feed 
among HCoV positive cases should be interpreted witd caution because these clinical signs form part of our study’s eligibility criteria.
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were fewer females than males and fewer with very severe 
compared to severe pneumonia. At least half of the HCoV 
positives presented with fever (58%) and nasal flaring (53%).
Clinical outcomes of HCoV-infected patients
Over a quarter of those positive for at least one HCoV were 
admitted to the high dependency unit and of those posi-
tive for OC43, 13.5% (n=10) died while 7.8% (n=10) and 
7.1% (n=7) died of those positive for NL63 and 229E, respec-
tively. A large proportion of these deaths were observed among 
those with underlying co-morbidities (Figure 1). None of the 
HCoVs were statistically significantly associated with any of the 
specific clinical signs or outcomes investigated (p-values>0.05) 
except death among NL63 cases (Table 2); however, we had 
limited power to detect associations given the small number 
of HCoV positive cases.
Co-infection with other respiratory viruses
About 47% (n=147) of the 314 HCoV cases were co-infected 
with other viral respiratory pathogens; respiratory syncytial 
virus (RSV) and human rhinovirus (HRV) jointly accounted 
for >50% of all HCoV coinfections with other pathogens. A 
similar coinfection pattern was observed for each HCoV tested 
(Figure 2). Throughout the surveillance period, there were three 
cases (one of NL63 and two of OC43) aged <1 year that were 
readmitted and tested positive for the same HCoV as the first 
admission. The NL63 readmission occurred 10 days after dis-
charge from the first admission while the OC43 readmissions 
were at 3 and 21 days after discharge from the first admission. 
The NL63 case had a discharge diagnosis of neonatal sepsis 
for the first admission and gastroenteritis plus lower respira-
tory tract infection (LRTI) for the readmission. One of the 
OC43 cases had a discharge diagnosis of LRTI for both admis-
sions while the other had immunosuppression plus malnutri-
tion in the first and immunosuppression plus septicaemia for the 
second admission.
Temporal patterns of different HCoVs
NL63 and OC43 were observed fairly consistently through-
out the surveillance period while fewer cases of HCoV-229E 
were observed from the middle of 2011 and it disappeared after 
2016 (Figure 3). The highest numbers of cases were observed 
in the periods April to June for NL63, June to September for 
OC43 and January to March for 229E. Pooling data for all 
Figure 1. Frequency distribution of discharge diagnosis for mortality cases admitted to Kilifi County Hospital, Kilifi, Kenya 2007–2019, 
by HCoV type. LRTI=lower respiratory tract infection, CHD=congenital heart disease, TB=Tuberculosis, GE=Gastroenteritis.
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Table 2. Unadjusted Odds Ratios (ORs) for demographic and clinical characteristics and the hospitalisation outcomes 
for children (under 5 years) admitted with severe or very severe pneumonia to Kilifi County Hospital, Kilifi, Kenya 2007-
2019 by the 3 HCoV types.
NL63 OC43 229E
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Age 0-11 months Ref Ref Ref
12-23 months 0.74 (0.39-1.42) 0.369 0.92 (0.59-1.45) 0.723 1.15 (0.71-1.86) 0.569
24-35 months 1.92 (1.02-3.61) 0.043 0.72 (0.35-1.48) 0.371 1.23 (0.63-2.39) 0.547
36-59 months 0.51 (0.16-1.65) 0.263 0.98 (0.51-1.89) 0.949 0.93 (0.43-2.03) 0.854
Sex Female Ref Ref Ref
Male 1.62 (1.01-2.60) 0.046 0.81 (0.58-1.14) 0.221 1.27 (0.86-1.88) 0.233
Cough No Ref Ref Ref
Yes 0.64 (0.38-1.08) 0.098 1.43 (0.86-2.39) 0.168 1.37 (0.78-2.42) 0.268
Breathing difficulty No Ref Ref Ref
Yes 0.63 (0.31-1.27) 0.196 0.83 (0.46-1.52) 0.544 1.38 (0.61-3.17) 0.440
Fever* No Ref Ref Ref
Yes 1.13 (0.72-1.78) 0.587 1.04 (0.73-1.46) 0.839 0.94 (0.65-1.38) 0.766
Prostration/ 
unconsciousness
No Ref Ref Ref
Yes 1.44 (0.83-2.46) 0.189 0.85 (0.52-1.39) 0.517 0.84 (0.49-1.46) 0.543
Chest indrawing No Ref Ref Ref
Yes 0.68 (0.33-1.37) 0.279 1.62 (0.75-3.48) 0.217 0.86 (0.44-1.65) 0.64
Inability to feed No Ref Ref Ref
Yes 0.54 (0.22-1.35) 0.189 0.71 (0.38-1.32) 0.283 0.62 (0.29-1.34) 0.226
Hypoxemia (O2<90%) No Ref Ref Ref
Yes 0.92 (0.51-1.67) 0.780 0.58 (0.34-0.99) 0.046 0.64 (0.34-1.14) 0.131
Pneumonia status Severe Ref Ref Ref
Very severe 1.22 (0.76-1.95) 0.406 0.71 (0.47-1.06) 0.094 0.71 (0.45-1.12) 0.143
Hospital stay <= 4 days Ref Ref Ref
> 4 days 1.06 (0.68-1.65) 0.807 0.85 (0.60-1.21) 0.373 0.72 (0.49-1.08) 0.110
Death No Ref Ref Ref
Yes 1.98 (1.02-3.87) 0.045 1.07 (0.56-2.05) 0.842 0.93 (0.43-2.03) 0.872
*Fever is defined as auxiliary temperature ≥37.5°C.
HCoVs, there were more cases in the colder months (May to 
September) than the hotter months (October to April) (Figure 4), 
as for OC43, but NL63 was more common in the first half 
of the year, and 229E in the second half of the year. How-
ever, time series models did not indicate a seasonal pattern for 
any of the HCoVs (Figure 5) over the years. The proportion 
of samples tested for HCoV did not change over time among 
those with severe pneumonia 2(1) 3.11;χ =  p-value = 0.078) but 
changed among those with very severe pneumonia 2(1) 149.11;χ =   p-value < 0.001).
De-identified raw data for this study are available as Underlying 
data18.
Discussion
We have described the circulation patterns of endemic HCoVs 
(NL63, OC43 and 229E) in a long-term surveillance study 
of childhood pneumonia hospitalisations in coastal Kenya. 
We observed a small proportion of pneumonia admissions 
positive for one or more HCoVs (3.9%). While 65% of HCoV 
infections occurred in children in their first year of life (either 
cumulatively for all HCoVs or for each individual HCoV type), 
this reflected the age-distribution of pneumonia admissions 
to the ward. Hence, contrary to other reports19, this suggests 
age is not a risk factor for coronavirus associated pneumonia 
hospital admission. Our reported prevalence is equivalent to that 
from a long-term hospital surveillance of seasonal coronaviruses 
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Figure 2. Percentage distribution of coinfections between HCoVs and other viral pathogens for pneumonia cases admitted to 
Kilifi County Hospital, Kilifi, Kenya 2007–2019. RSV=respiratory syncytial virus (A and B), HRV=human rhinovirus, PIV=parainfluenza, 
FLU=influenza (A, B and C), hMPV= human metapneumovirus.
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Figure 3. Monthly prevalence (%) pneumonia admissions at Kilifi County Hospital, Kilifi, Kenya 2007–2019 by HCoV type. The panel 
shows proportions for all HCoVs (a), NL63 (b), OC43 (c) and 229E (d).
Figure 4. Proportion of monthly positive cases observed at Kilifi County Hospital, Kilifi, Kenya by HCoV type over a period of 
13 years (2007–2019). The primary y-axis denotes the proportion of samples positive for HCoV and the average monthly maximum 
temperature in °C while the secondary y-axis denotes the average monthly rainfall in millimetres.
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Figure 5. Plot of time series model residuals against month separated by HCoV type using pneumonia surveillance data at Kilifi 
County Hospital, Kilifi, Kenya 2007–2019. See Methods for statistical details.
in Scotland (4%)8 but lower compared to a multi-centre 
study across Kenya for the same three HCoVs (26/417 6.2% 
versus 314/7643 3.9%; 2(1) 5.33,χ =  p-value=0.021)
7
. This lat-
ter study included locations with a wide range of climate 
conditions that might influence prevalence; however, the 
study was not big enough to stratify by location.
We did not observe seasonal variation of HCoVs compared 
to some other respiratory viral pathogens like RSV, as pre-
viously reported from our site14. In addition, neither peak 
months for pneumonia admissions nor the long rain periods 
(April to July) in Kilifi translated to HCoV peaks. This is in 
contrast to data from temperate settings where seasonality of 
HCoVs has been reported8,20–22, with increased occurrence dur-
ing the colder winter months. The HCoVs we have studied are 
known to continuously circulate among humans1, although 
in Kilifi we observed low numbers for all types. Of interest 
is that pneumonia associated with 229E admissions faded out 
in the later years of the surveillance. We attempted to investi-
gate if this was due to primers or probe mismatches. For all the 
three tested endemic CoVs we did not observe significant mis-
matches on the primer/probe pairs against data available from 
GenBank database although this investigation suffered a limi-
tation of few sequences available globally in recent years 
(2015–2019) and none from East Africa. With the highest num-
bers and consistent presence compared to NL63 and 229E, our 
results suggest that OC43 is the predominant HCoV type in the 
coastal region of Kenya.
The present study did not have a control group by which to 
assess an aetiological association between the HCoVs and 
pneumonia. In the PERCH multi-country case-control study17 
HCoVs contributed less than 1% of the etiological fraction. 
In our study the contribution to disease is not known (except 
for the relatively small set of samples from 2011–13 that were 
part of the PERCH study), but it is of note that around 50% 
co-occurred with another respiratory virus (most commonly 
with RSV), the risk was not age-dependent, there was no clear 
association between any of the viruses with the any of the spe-
cific clinical signs or outcomes investigated and in 26% of 
deaths with a HCoV detected there was a likely alternative 
diagnosis to pneumonia. While we have been able to sequence 
the virus from a proportion of the positive specimens23,24, we 
cannot assume 100% specificity, and even a modest level of 
false positivity could account for many of the positive diag-
noses and argues for caution in interpreting the prevalence esti-
mates. Of relevance also is that few (~1%) of the 314 children 
positive for at least one HCoV were subsequently HCoV-positive 
readmissions. While this is a crude analysis which ignores 
censoring at the start and end of the surveillance, and alter-
native hospitals where patients may have been admitted, it 
might be an indicator of low probability of severe reinfection.
Over the surveillance period, we have changed our sample col-
lection and testing methods. This is a limitation; we did not 
conduct a sensitivity analysis to compare the different PCR 
methods, and the addition of an OP swab increases the number 
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•     GPOtieno_HCOV_Codebook (PDF). (Data dictionary and 
codebook.)
The data have been de-identified, and hence lack person-
ally identifiable information. To request access to additional 
variables from this dataset go to ‘Data Governance’ on http://
kemri-wellcome.org/about-us/#ChildVerticalTab15 and sub-
mit an ‘External Request’ to the Data Governance Committee 
(dgc@kemri-wellcome.org).
Extended data
Harvard Dataverse: Replication Data for: Surveillance of 
endemic human coronaviruses (HCoV-NL63, OC43 and 229E) 
associated with pneumonia in Kilifi, Kenya. https://doi.org/10.7910/
DVN/ZQ1DJY18.
This project contains the following extended data: 
•     1_descriptive_analysis (DO). (Scripts used to generate 
information in the tables, data on frequencies, HCOVs 
virus distributions and proportions.)
•     2_graph_outputs (DO). (Code used to generate charts in 
the paper.)
•     3_ORs (DO). (Code to fit univariable logistic regression 
models for each HCoV type.)
•     4_seasonality (DO). (scripts for analyses of HCoV type 
seasonality.)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
Acknowledgments
We thank the study participants and their parents/ guardians, 
clinical and research team members of the Virus Epidemiol-
ogy and Control group (http://virec-group.org/) who were 
involved at various stages of this study including sample col-
lection and processing. This paper has been approved for 
publication by the director of the Kenya Medical Research 
Institute.
Page 10 of 17
Wellcome Open Research 2020, 5:150 Last updated: 21 JUL 2020
acute respiratory syndrome. Lancet. 2003; 361(9366): 1319–25.  
PubMed Abstract | Publisher Full Text | Free Full Text 
10.  Raj VS, Osterhaus ADME, Fouchier RAM, et al.: MERS: emergence of a novel 
human coronavirus. Curr Opin Virol. 2014; 5: 58–62.  
PubMed Abstract | Publisher Full Text | Free Full Text 
11.  World Health Organization: Coronavirus. [cited 2020 Mar 20].  
Reference Source
12.  Fehr AR, Perlman S: Coronaviruses: An Overview of Their Replication and 
Pathogenesis. Methods Mol Biol. 2015; 1282: 1–23.  
PubMed Abstract | Publisher Full Text | Free Full Text 
13.  Scott JAG, Bauni E, Moisi JC, et al.: Profile: The Kilifi Health and Demographic 
Surveillance System (KHDSS). Int J Epidemiol. 2012; 41(3): 650–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
14.  Nokes DJ, Ngama M, Bett A, et al.: Incidence and Severity of Respiratory 
Syncytial Virus Pneumonia in Rural Kenyan Children Identified through 
Hospital Surveillance. Clin Infect Dis. 2009; 49(9): 1341–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
15.  Hammitt LL, Kazungu S, Welch S, et al.: Added Value of an Oropharyngeal Swab 
in Detection of Viruses in Children Hospitalized with Lower Respiratory Tract 
Infection. J Clin Microbiol. 2011; 49(6): 2318–20.  
PubMed Abstract | Publisher Full Text | Free Full Text 
16.  Kamau E, Agoti CN, Lewa CS, et al.: Recent sequence variation in probe binding 
site affected detection of respiratory syncytial virus group B by real-time RT-
PCR. J Clin Virol. 2017; 88: 21–5.  
PubMed Abstract | Publisher Full Text | Free Full Text 
17.  Pneumonia Etiology Research for Child Health (PERCH) Study Group: Causes 
of severe pneumonia requiring hospital admission in children without HIV 
infection from Africa and Asia: the PERCH multi-country case-control study. 
Lancet. 2019; 394(10200): 757–79.  
PubMed Abstract | Publisher Full Text | Free Full Text 
18.  Otieno GP, Murunga N, Agoti C, et al.: Replication Data for: Surveillance of 
endemic human coronaviruses (HCoV-NL63, OC43 and 229E) associated with 
pneumonia in Kilifi, Kenya. Harvard Dataverse. 2020.  
http://www.doi.org/10.7910/DVN/ZQ1DJY
19.  Ogimi C, Englund JA, Bradford MC, et al.: Characteristics and Outcomes 
of Coronavirus Infection in Children: The Role of Viral Factors and an 
Immunocompromised State. J Pediatr Infect Dis Soc. 2019; 8(1): 21–8.  
PubMed Abstract | Publisher Full Text | Free Full Text 
20.  Gaunt ER, Hardie A, Claas ECJ, et al.: Epidemiology and Clinical Presentations 
of the Four Human Coronaviruses 229E, HKU1, NL63, and OC43 Detected over 
3 Years Using a Novel Multiplex Real-Time PCR Method. J Clin Microbiol. 2010; 
48(8): 2940–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
21.  Hoek LVD, Pyrc K, Berkhout B: Human coronavirus NL63, a new respiratory 
virus. FEMS Microbiol Rev. 2006; 30(5): 760–73.  
PubMed Abstract | Publisher Full Text | Free Full Text 
22.  Aldridge RW, Lewer D, Beale S, et al.: Seasonality and immunity to laboratory-
confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): 
results from the Flu Watch cohort study [version 1; peer review: 2 approved 
with reservations]. Wellcome Open Res. 2020; 5: 52.  
Publisher Full Text 
23.  Kamau E, Luka MM, Laurent ZR de, et al.: Genome Sequences of Human 
Coronavirus OC43 and NL63, Associated with Respiratory Infections in Kilifi, 
Kenya. Microbiol Resour Announc. 2019; 8(46): e00730-19.  
PubMed Abstract | Publisher Full Text | Free Full Text 
24.  Kiyuka PK, Agoti CN, Munywoki PK, et al.: Human Coronavirus NL63 Molecular 
Epidemiology and Evolutionary Patterns in Rural Coastal Kenya. J Infect Dis. 
2018; 217(11): 1728–39.  
PubMed Abstract | Publisher Full Text | Free Full Text 
25.  Killerby ME, Biggs HM, Haynes A, et al.: Human coronavirus circulation in the 
United States 2014-2017. J Clin Virol. 2018; 101: 52–6.  
PubMed Abstract | Publisher Full Text | Free Full Text 
Page 11 of 17







  Current Peer Review Status:
Version 1
 21 July 2020Reviewer Report
https://doi.org/10.21956/wellcomeopenres.17592.r39427






























Page 12 of 17






















































Is the work clearly and accurately presented and does it cite the current literature?
Yes
1
Page 13 of 17
Wellcome Open Research 2020, 5:150 Last updated: 21 JUL 2020
 1.  
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes





I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however I have significant
reservations, as outlined above.
 06 July 2020Reviewer Report
https://doi.org/10.21956/wellcomeopenres.17592.r39270
© 2020 Moore D. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution License
work is properly cited.














Page 14 of 17


































































Page 15 of 17




































































Page 16 of 17













Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes




I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however I have significant
reservations, as outlined above.
Page 17 of 17
Wellcome Open Research 2020, 5:150 Last updated: 21 JUL 2020
